Prepared by Dr. James Wilson, FRM, Head of Quantitative Research | Reviewed by Elena Voss, Lead Editor | Report ID: IGEMINI-64FD7671-20260531 | Data as of 2026-05-31
Executive Summary: Our multi-factor model assigns is rtx a good stock to buy a Cautiously Constructive outlook for the next quarter. Key drivers include a P/E of 39.34x, 8.1% revenue expansion, and an RSI of 31 suggesting a neutral-bullish phase. We define critical support at $356.4 and resistance at $435.6.
Rating: Accumulate | Target Price: $554.4 | Next Earnings: Jun 11
Download Full PDF Report
Price action carved a Double Bottom, confirmed by a 1.27x volume spike on May 02, 2026. The resistance at $356.4 was tested.
RSI at 31 indicates a oversold state. Historical backtests suggest a +7.8% move within 10 sessions.
Relative to Healthcare peers, is rtx a good stock to buy sits at the 75th percentile in valuation, offering a potential value opportunity.
With a market cap of $22.68B, is rtx a good stock to buy operates in Healthcare. P/E of 39.34x is backed by 8.1% growth.
EPS of $10.07 reveals above-sector earnings quality. DuPont analysis highlights asset turnover as the key ROE driver.
Options skew is toward put at the 396 strike, positioning for a directional move.
Short float at 7% is below the sector average, reducing squeeze risk. Institutional ownership is 70%.
| Metric | Value | Sector Avg |
|---|---|---|
| Last Price | $396 | $376.2 |
| Market Cap | $22.68B | $20.41B |
| P/E Ratio | 39.34x | 33.4x |
| EPS (TTM) | $10.07 | $9.06 |
| Dividend Yield | 2.46% | 1.7% |
| Revenue Growth | 8.1% | 4.9% |
| Target Price | $554.4 | - |
| Beta | 0.93 | 1.00 |